Dear Customers and Friends of Omixon,

 

After a prosperous finish to 2016, I would like you to be the first to know about three major announcements concerning Omixon’s evolution for 2017, in the HLA community and beyond.

First, in the next few weeks, we will be launching Holotype HLA V2 (announced at ASHI 2016) and HLA Twin V2.1, the latest version of our NGS-based HLA genotyping assay and software. This is considered a ‘major product release’ and this version will be submitted as part of our update to our IVD CE Mark for Europe. In additional regulatory news, Omixon has begun certification for Health Canada as part of the conditions of our successful tender with Hema Quebec – we look forward to spending even more time in Canada!

One year ago, Omixon announced its major victory in being selected as the NGS provider to all the labs of the Etablissement Français du Sang (the French National Blood Service, EFS). We are delighted that after a first successful year of operation, EFS are expanding the number of regions in France using Holotype HLA, with multiple new labs moving into routine – a direct reflection of their happiness with our product and the quality and dedication provided by our amazing FAS and Support Teams! We welcome all the new labs into the Omixon family and look forward to helping these happy Holotypers every way we can!

Our third announcement is our commitment to bringing new products to the HLA community – through our existing collaboration channels with the Children’s Hospital of Philadelphia, with other HLA labs that are developing new applications from exciting technologies, and via partnerships organised by our outstanding Business Development Team, Omixon will have some products we think will change your current workflows in ways just as revolutionary as NGS!

Join our Omixon Odyssey in 2017 at any of the major immunogenetics conferences or by requesting a site visit from our Sales Team today!

Cheers!

Tim